Global Information
회사소개 | 문의 | 비교리스트

다낭성 신장질환(PKD) : 파이프라인 리뷰

Polycystic Kidney Disease - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 192782
페이지 정보 영문 127 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


다낭성 신장질환(PKD) : 파이프라인 리뷰 Polycystic Kidney Disease - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 127 Pages

다낭성 신장질환(PKD)이란 주로 신장 내부에 낭포가 밀집하여 발생하는 질환입니다. 주요 징후로 고혈압 및 등·옆구리 통증, 두통, 혈뇨, 빈뇨, 신부전 등을 들 수 있습니다. 질병 소질에는 연령 및 가족력 등이 포함됩니다. 주요 치료제에는 항고혈압제 및 이뇨제 등이 있습니다.

세계 각국에서의 다낭성 신장질환(다낭포성 신장질환) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

다낭성 신장질환 개요

치료제 개발

  • 파이프라인 제품의 개요
  • 파이프라인 제품 : 기업별
  • 파이프라인 제품 : 대학/기관별
  • 기업에서 개발중인 제품
  • 대학/기관에서 연구중인 제품

다낭성 신장질환 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

다낭성 신장질환 치료제 개발에 참여하고 있는 기업

  • Angion Biomedica Corp
  • Aptevo Therapeutics Inc
  • Celgene Corp
  • Conatus Pharmaceuticals Inc
  • DiscoveryBiomed Inc
  • Endocyte Inc
  • IC-MedTech Inc
  • Ipsen SA
  • Kadmon Corp LLC
  • Madrigal Pharmaceuticals Inc.
  • ManRos Therapeutics
  • Metabolic Solutions Development Company LLC
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • Otsuka Holdings Co Ltd
  • Q BioMed Inc
  • Regulus Therapeutics Inc
  • XORTX Pharma Corp

약제 개요

다낭성 신장질환 : 휴지중인 프로젝트

다낭성 신장질환 : 개발이 중지된 제품

다낭성 신장질환 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.11.02

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Polycystic Kidney Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Polycystic Kidney Disease - Pipeline by AceLink Therapeutics Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H1 2020
  • Polycystic Kidney Disease - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by Eloxx Pharmaceuticals Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by Genzyme Corp, H1 2020
  • Polycystic Kidney Disease - Pipeline by GLG Pharma SA, H1 2020
  • Polycystic Kidney Disease - Pipeline by Goldfinch Biopharma Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by Ipsen SA, H1 2020
  • Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H1 2020
  • Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H1 2020
  • Polycystic Kidney Disease - Pipeline by Mironid Ltd, H1 2020
  • Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by Palladio Biosciences Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by Reata Pharmaceuticals Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H1 2020
  • Polycystic Kidney Disease - Pipeline by XORTX Therapeutics Inc, H1 2020
  • Polycystic Kidney Disease - Dormant Projects, H1 2020
  • Polycystic Kidney Disease - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Polycystic Kidney Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2020, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 3, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Polycystic Kidney Disease - Overview
  • Polycystic Kidney Disease - Therapeutics Development
  • Polycystic Kidney Disease - Therapeutics Assessment
  • Polycystic Kidney Disease - Companies Involved in Therapeutics Development
  • Polycystic Kidney Disease - Drug Profiles
  • Polycystic Kidney Disease - Dormant Projects
  • Polycystic Kidney Disease - Discontinued Products
  • Polycystic Kidney Disease - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q